Pharmaceuticals) against the tenative liability of Rs. 205.36 lakhs for the period upto 31.12.83, already communicated to it, is under consideration and the final decision will be communicated soon. The data for the subsequent period is still awaited from the company.

Duty conctssions on bulk drugs and formulations

2080. SHRIMATI SATYA BAHIN: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 566 given in the Rajya Sabha on the 5th September, 1991 and state:

(a) what are the names of bulk drugs or formulations where the objective has been achieved based on duty concession granted by Government during the last three years;

(b) what are the names of Bulk drugs which are being produced from Basic stage and names of imported formulations being indigenously produced after grant of duty concessions;

(c) whether duty concessions have any bearing on the price structure of price controlled and decontrolled bulk drug and formulations; and

(d) if so, what are the names of those bulk drugs and formulations where prices have been reduced linked to Custom Duty reduction effected by Governmen during the last three years including the current year?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (d) The names of bulk drugs and drug intermediates on which customs duty concessions have been given by the Ministry of Finance during the last three years are given in the customs notifications published from time to time in the official Gazette, copies of which are available in the Parliament Library. Proposals of customs duty concessions are examined in this Deptt. before sending any recommendation in this regard to Ministry of Finance. The recommendation as finally accepted by the Ministry of Finance are taken into account while fixing the price of controlled bulk drugs and formulations Major objective of duty rationalisaton to encourage production from a mor basic stage. This reduction in duty is no linked necessarily in every case to reduc tion in prices of bulk drugs and formula tions.

Abolition of loan licensing system in Pharmaceuticals

2081. SHRI SURESH KALMADI: Wi the PRIME MINISTER be pleased t state:

(a) whether it is a fact that loan licer sing system in pharmaceuticals is propose to be abolished from 31st December, 199

(b) if so, the reasons therefor;

(c) the number of persons who woul be affected by abolition of this system an how they would be rehabilitated; and

(d) whether this abolition affect the ove all availability of drugs in the country?

THE MINISTER OF STATE IN TH MINISTRY OF CHEMICALS AND FEI TILIZERS (SHRI CHINTA MOHAN

(a) to (d) The matter regarding discor tinuation of loan licence system fro 1-1-1992 is being re-examined comprehei sively in the light of representations/su gestions received in this regard from th manufacturers/drug industry association

Wrong exclusion of bulk drugs Kelkar Committee

2082. SHRIMATI BIJOYA CHAI RAVARTY: Will the PRIME MINISTE be pleased to refer to the answer t Unstarred Question 688 given in th Rajya Sabha on the 5th Septembe 1991 and state:

(a) what are the details of represen tations received by Government again wrong exclusion of bulk drugs by Kelka Committee;

(b) when each of the representation was received and from whom;

(c) when did the committee conside the representations and what were th

findings of the committee on each of these bulk drugs;

(d) whether Government have taken any decision on the findings of the Standing Committee; and

(e) if so, the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (e) Sir, a large number of representations pointing out various anomalies in the Kelkar Committee, including wrong inclusion/ exclusion of bulk drugs from price control under DPCO 1987, have been received. All these representations have been since examined by the Standing Committee whose recommendations are presently under consideration of the Government.

Imposition of duly and withdrawal of duty exemption on bulk drugs and inputs of drugs

2083. SHRIMATI BIJOYA CHAKRAVARTY: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 667 given in the Rajya Sabha on the 5th September, 1991 and state:

(a) what are the names of bulk drugs and inputs of drugs where Government have received requests for imposing of duty and withdrawing of duty exemption during 1991;

(b) whether it is a fact that availability of drug for Aids i.e. AZT is held up on account of duty exemption on its input;

(c) if so, what action has been taken by Government;

(d) whether it is also a fact that Government have received requests for imposition of duty on Vinblastine Vincrestine, Danazol and Etoposide;

(e) if so, the action taken thereon;

(f) whether it is also a fact that custom duty is zero on Etoposide formulations and excise duty on inputs for Production of bulk drug; and

(g) if so, what steps have been taken to take uniform action?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) Duty rationalisation on bulk drugs, intermediates and finished medicines is an on going process. Requests for hike or reduction in duty keep on coming and after consideration and examination in this Department, these are recommended to Department of Revenue which takes final decision in this regard.

(b) and (c) The proposal for duty exemption on import of inter-mediate for bulk drug AZT was sent to Ministry of Finance in May, 1991.

(d) and (e) The Government have received the request for imposition of duty on formulations of Etoposide only which is under consideration and examination.

(f) and (g) Yes, Sir. The request for withdrawal of customs duty concession on Etoposide formulatios and excise duty exemption on Etoposide bulk drug is under consideration and examination.

Revision of prices of drugs

2084. SHRI R. S. NAIK: Will the PRIME MINISTER be pleased to state:

(a) what are the names of drugs where Government have revised the prices from 1st January, 1991 to 30th November, 1991;

(b) what was the price of each before revision and what is the present price;

(c) what are the names of drugs where prices have been revised based on the recommendations of BICP and when recommendation was received;

(d) what are the names of drugs where Government revised prices on *suo motto* basis without any cost-cum-technical study and what is the percentage of increase in each case;

(e) whether it is a fact that *suo-motto* situation has been used to obtain dealer-